Latest Breaking News On - Rev gastroenterol hepatol - Page 1 : comparemela.com

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesKori wallaceVan asscheEdouard louisGastroenterol hepatolExchange commissionUniversity hospitalNational institute of diabetesBoehringer ingelheimAssociation between disease activityEuropean medicines agencyEuropean commissionCommittee for medicinal products human useDrug administrationEuropean unionCrohn colitis foundation of america

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

Takeda TSE4502NYSETAK today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval of fruquintinib a selective inhibitor of vascular endothelial growth factor receptors VEGFR 1 2 and 3 for the treatment of adult patients with previously treated metastatic colorectal cancer mCRC.

United statesHong kongAl qahirahAwny farajallahJun saitoAhcene djaballahGastroenterol hepatolCommittee for medicinal products human useDrug administrationEuropean unionTakeda pharmaceuticalsJapan pharmaceuticalsDevices agencyExchange commissionInternational normalized ratioEuropean medicines agency

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda

HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesHong kongAl qahirahWeiguo suAhcene djaballahDaphne zhangFreddy crossleyAtholl tweedieGastroenterol hepatolZhou yiAwny farajallahEli lillyBen atwell alex shawChina national reimbursement drug listAmerican cancer societyChina limited

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer

− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over a Decade − Positive Opinion.

Al qahirahUnited statesHong kongAhcene djaballahGastroenterol hepatolAwny farajallahTakeda pharmaceuticalsDrug administrationEuropean commissionJapan pharmaceuticalsExchange commissionEuropean medicines agencyAmerican cancer societyInternational agency for research on cancerInternational normalized ratioCommittee for medicinal products human use

HUTCHMED Receives ELUNATE® (fruquintinib) Marketing

First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong ELUNATE® is.

Hong kongAl qahirahUnited statesStephen chanCaron liAhcene djaballahGastroenterol hepatolZhou yiKaren atkinBen atwell alex shawExchange commissionDrug administrationStock exchange of hong kongChina limited nasdaqJournal of the american medical associationChina national medical products administration